Sharekhan

Brooks Laboratories Ltd

Wed 30/04/2025,15:48:36 | NSE : BROOKS

₹ 132.10-1.84 (-1.37%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 136.65

Previous Close

₹ 133.94

Volume

8961

Mkt Cap ( Rs. Cr)

₹389.13

High

₹ 136.65

Low

₹ 129.00

52 Week High

₹ 198.86

52 Week Low

₹ 73.25

Book Value Per Share

₹ 21.19

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Brooks Laboratories Ltd

Your Vote -

Buy

22.22%

Hold

5.56%

Sell

72.22%

22.22%

36 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

139.77

605

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

605

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Brooks Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Brooks Laboratories - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    29 Apr 2025, 3:04PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Brooks Laboratories - Intimation Of Update In Registrar And Transfer Agent (RTA) Contact Details

    19 Apr 2025, 11:50AM Change in RTA Contact information. Details provided in the attachment.
  • Brooks Laboratories - Updates

    19 Apr 2025, 11:40AM Brooks Laboratories Limited has informed the Exchange regarding 'Change in Registrar and Transfer Agent (RTA) Contact Information'.
  • Brooks Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    17 Apr 2025, 8:20PM As of March 2025, 52.62% is owned by Indian Promoters and 47.38% by Public. <p align=justify> Top five Promoters holding highest number of shares of B
  • Brooks Laboratories - Disclosure under SEBI Takeover Regulations

    11 Apr 2025, 6:41PM Rajesh Mahajan has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac
  • Brooks Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 5:49PM Please find enclosed copy of the certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
  • Brooks Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 5:32PM Kindly find attached copy of the certificate under Reg. 74(5) of SEBI(DP) Regulation 2018.
  • Brooks Laboratories - Trading Window-XBRL

    26 Mar 2025, 12:58PM BROOKS LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window
  • Brooks Laboratories - Trading Window

    26 Mar 2025, 12:45PM Brooks Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio
  • Brooks Laboratories - Reply to Clarification- Financial results

    7 Mar 2025, 2:40PM The Exchange had sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Li
  • Brooks Laboratories - Clarification - Financial Results

    4 Mar 2025, 5:31PM The Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Li
  • Brooks Laboratories - Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December, 2024 (Revised).

    28 Feb 2025, 6:08PM Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.
  • Brooks Laboratories - Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December, 2024 (Revised).

    28 Feb 2025, 6:07PM Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.
  • Brooks Laboratories - General Updates

    28 Feb 2025, 5:54PM Brooks Laboratories Limited has informed the Exchange about General Updates Integrated Filing (Financial) for the quarter and nine months ended 31st D
  • Brooks Laboratories - Outcome Of Board Meeting (Revised).

    25 Feb 2025, 7:07PM Revision of the outcome of the Board Meeting held on 13th February 2025.
  • Brooks Laboratories - Updates

    25 Feb 2025, 7:00PM Brooks Laboratories Limited has informed the Exchange regarding, revision in outcome of the Board Meeting held on 13th February 2025.
  • Brooks Laboratories - Copy of Newspaper Publication

    14 Feb 2025, 12:00PM Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated
  • Brooks Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended January 29, 2025

    14 Feb 2025, 7:03AM As of January 2025, 52.62% is owned by Indian Promoters and 47.38% by Public. <p align=justify> Top five Promoters holding highest number of shares of
  • Brooks Laboratories - Integrated Filing- Financial

    13 Feb 2025, 6:53PM Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024
  • Brooks Laboratories - Integrated Filing (Financial)

    13 Feb 2025, 6:50PM Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024.
  • Brooks Laboratories Q3 net profit up 24.14% at Rs 0.72 cr

    13 Feb 2025, 6:20PM The company reported standalone net profit of Rs 0.72 crore for the quarter ended December 31, 2024 as compared to Rs 0.58 crore in the same period la
  • Brooks Laboratories - Financial Result Updates

    13 Feb 2025, 5:59PM Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Brooks Laboratories - Outcome of Board Meeting

    13 Feb 2025, 5:52PM Brooks Laboratories Limited has informed the Exchange regarding Board meeting held on February 13, 2025 to consider and approve unaudited financial r
  • Brooks Laboratories - Unaudited Financial Results, Both Standalone And Consolidated, For The Quarter And Nine Months Ended 31

    13 Feb 2025, 5:46PM Unaudited Financial results, both standalone and consolidated for the quarter and nine months ended 31st December 2024.
  • Brooks Laboratories - Board Meeting Outcome for Board Meeting Outcome Under Regulation 30 & Regulation 33 Of SEBI (Listing O

    13 Feb 2025, 5:39PM Outcome of Board Meeting under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Brooks Laboratories - Board Meeting Intimation

    10 Feb 2025, 7:25PM BROOKS LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 13-Feb-2025 to inter-alia consider and approve the Unaudited F
  • Brooks Laboratories - Board Meeting Intimation for Intimation Under Regulation 29 Of The SEBI (Listing Obligation And Disclos

    10 Feb 2025, 7:00PM BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 ,inter alia, to consider

Key fundamentals

Evaluate the intrinsic value of Brooks Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 74.5735 62.4424 69.9259 72.3712 122.4256
Liabilities 74.5735 62.4424 69.9259 72.3712 122.4256
Equity 26.2467 24.7028 24.7028 24.7028 24.7028
Gross Profit 3.2173 -5.8143 1.8744 0.7638 -3.9221
Net Profit 1.5287 -8.1912 0.666 -15.5876 -24.376
Cash From Operating Activities -9.6806 0.5622 3.1235 -0.8986 -9.3887
NPM(%) 1.92 -14.74 0.86 -20.17 -34.97
Revenue 79.4861 55.538 76.9672 77.2469 69.6885
Expenses 76.2688 61.3523 75.0928 76.4831 73.6106
ROE(%) 2.44 -13.12 1.06 -24.97 -39.05

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Brooks Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 825.75 -1.80 11.65 75.91 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 81.22 -0.17 338.42 276.59 14.01 0.62
Vaishali Pharma Ltd 13.47 -1.82 449.00 142.57 2.76 0.00
Astec Lifesciences Ltd 685.90 -1.03 0.00 260.80 -687.11 0.00

Company Info

Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.

Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.

Read More

Parent Organisation

Brooks Laboratories Ltd.

Founded

23/01/2002

Managing Director

NSE Symbol

BROOKSBE

FAQ

The current price of Brooks Laboratories Ltd is ₹ 132.10.

The 52-week high for Brooks Laboratories Ltd is ₹ 136.65 and the 52-week low is ₹ 129.00.

The market capitalization of Brooks Laboratories Ltd is currently ₹ 389.13. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Brooks Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Brooks Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Brooks Laboratories Ltd shares.

The CEO of Brooks Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT